Truth of an industry and the transparency of a profession

GlaxoSmithKline is fined record $3bn in US, published 3 July 2012, as:BMJ2012;345:e4568

http://www.bmj.com/content/345/bmj.e4568

Reply by Dr Peter J Gordon as rapid-response to the BMJ, 10th July 2012: http://www.bmj.com/content/345/bmj.e4568/rr/593464

£3 billion

Truth of an industry and the transparency of a profession
I am not a campaigner against the pharmaceutical industry and support pharmaceutical innovation and development. However I am shocked by the 212 exhibits now available for all to see following the whistleblower lawsuit against GlaxoSmithKline, for which the company has pled guilty and agreed to pay $3bn in penalties for unlawful promotion of prescription drugs and failure to report safety data[1]. The Chairman of GSK has admitted ‘regret’ but has offered no apology.

Let us consider TRUTH and the pharmaceutical industry. Here we must mull over: ‘misleading’ journal articles; the deliberate concealment of negative trial results; the illegal promotion of off-label uses of drugs; and the culture of promotion that makes profit the prime consideration.

Now let us consider TRANSPARENCY. Here we need to ask: Do the public have open access to hospitality registers and where is the General Medical Council support of this? Do the public know how entangled our continuing medical education is with the pharmaceutical Industry? Can we be reassured by Richard Thompson chair of the Ethical Standards in Health and Life Sciences Group given their recent controversial guideline to ‘promote collaboration between doctors and the pharmaceutical industry’?[2] Can we agree with them that the pharmaceutical industry plays a ‘valid and important role in the provision of medical education’? Are we reassured by Stephen Whitehead, Chief Executive of Association of the British Pharmaceutical Industry that the ‘Drug industry takes great care to be a responsible healthcare partner’?[3] And finally are our leading medical journals transparent when it comes to reprint sales that are so strongly associated with pharmaceutical funding?[4]

I would urge readers to look at the 212 exhibits presented for this law-suit and to ask a final question: does our continuing medical education need the pharmaceutical industry?

fair to conclude

My short film on this: A series of exhibits: https://vimeo.com/45512456


[1] BMJ2012;345:e4568 GlaxoSmithKline is fined record $3bn in US. Published 3 July 2012

[2] BMJ2012;344:e3371 Guidance on collaboration with drug industry Towards greater transparency in the life sciences. Published 15 May 2012

[3] BMJ2011;343:d6695 Drug industry takes great care to be responsible healthcare partner Published 26 October 2011

[4] Medical journals: a gaggle of golden geese Blog by Richard Smith. 3 July 2012. by BMJ Group

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s